Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-384.04%
operating margin TTM
-455.79%
revenue TTM
13.42 Million
revenue per share TTM
0.35$
valuation ratios | |
|---|---|
| pe ratio | -1.74 |
| peg ratio | 0.24 |
| price to book ratio | 0.40 |
| price to sales ratio | 6.30 |
| enterprise value multiple | -2.31 |
| price fair value | 0.40 |
profitability ratios | |
|---|---|
| gross profit margin | 98.25% |
| operating profit margin | -455.79% |
| pretax profit margin | -348.67% |
| net profit margin | -384.04% |
| return on assets | -19.57% |
| return on equity | -22.15% |
| return on capital employed | -24.67% |
liquidity ratio | |
|---|---|
| current ratio | 12.62 |
| quick ratio | 12.62 |
| cash ratio | 3.52 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 38.49 |
| days of payables outstanding | 5,071.23 |
| cash conversion cycle | -5,032.74 |
| receivables turnover | 9.48 |
| payables turnover | 0.07 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.01 |
| debt equity ratio | 0.01 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.01 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -19.27 |
cash flow ratios | |
|---|---|
| free cash flow per share | -2.47 |
| cash per share | 12.22 |
| operating cash flow per share | -2.43 |
| free cash flow operating cash flow ratio | 1.02 |
| cash flow coverage ratios | -19.27 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -60.12 |
Frequently Asked Questions
When was the last time iTeos Therapeutics, Inc. (NASDAQ:ITOS) reported earnings?
iTeos Therapeutics, Inc. (ITOS) published its most recent earnings results on 12-11-2024.
What is iTeos Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. iTeos Therapeutics, Inc. (NASDAQ:ITOS)'s trailing twelve months ROE is -22.15%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. iTeos Therapeutics, Inc. (ITOS) currently has a ROA of -19.57%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did ITOS's net profit margin stand at?
ITOS reported a profit margin of -384.04% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is ITOS's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 12.62 in the most recent quarter. The quick ratio stood at 12.62, with a Debt/Eq ratio of 0.01.